Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone

International Journal of Antimicrobial Agents

Volumn 23, Issue 1, 2004, Pages 6-10

  Anderegg, Tamara R ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AZD2563; Guideline; MIC

Indexed keywords

AGAR; LINEZOLID; OXAZOLIDINONE DERIVATIVE; POSIZOLID;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CORRELATION ANALYSIS; DIFFUSION; DILUTION; DRUG RESISTANCE; DRUG SENSITIVITY; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0345829296     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.05.007     Document Type: Article

References (22)

1. Chen D.K., McGeer A., de Azavedo J.C., Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. New Engl. J. Med. 341:1999;233-239.
2. Low D.E., Keller N., Barth A., Jones R.N. Clinical prevalence, antimicrobial susceptibility and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32:2001;S133-S145.
3. Walsh T.R., Bolmstrom A., Qwarnstrom A., Ho P., Wootton M., Howe R.A. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin. Microbiol. 39:2001;2439-2444.
4. Brickner S.J., Hutchinson D.K., Barbachyn M.R., Manninen P.R., Ulanowicz D.A., Garmon S.A. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections. J. Med. Chem. 39:1996;673-679.
5. ®) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn. Microbiol. Infect. Dis. 30:1998;437-451.
6. Jones R.N., Hare R.S., Sabatelli F.J. The Ziracin Susceptibility Testing Group. In vitro Gram-positive antimicrobial activity of everninomicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial. J. Antimicrob. Chemother. 47:2001;15-25.
7. Diekema D.J., Jones R.N. Oxazolidinone antibiotics. Lancet. 358:2001;1975-1982.
8. Gemmell C.G. Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J. Antimicrob. Chemother. 48:2001;47-52.
9. ® antimicrobial potency study (ZAPS) in the United States. Diagn. Microbiol. Infect. Dis. 40:2001;59-66.
10. Johnson A.P., Warner M., Livermore D.M. In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci. J. Antimicrob. Chemother. 50:2002;89-93.
11. Ednie L.M., Jacobs M.R., Applebaum P.C. Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents. J. Antimicrob. Chemother. 50:2002;101-105.
12. Peric M., Lin G., Clark C.L., Jacobs M.R., Applebaum P.C. Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents. J. Antimicrob. Chemother. 50:2002;95-100.
13. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial disk susceptibility tests, 8th ed. Approved standard M2-A7. Wayne, PA: NCCLS; 2003.
14. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard M7-A5. Wayne, PA: NCCLS; 2003.
15. National Committee for Clinical Laboratory Standards (NCCLS). Development of in vitro susceptibility testing criteria and quality control parameters, 2nd ed. Approved standard M23-A2. Wayne, PA: NCCLS; 2001.
16. Gonzales R.D., Schreckenberger P.C., Graham M.B., Kelkar S., DenBesten K., Quinn J.P. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet. 357:2001;1179.
17. Tsiodras S., Gold H.S., Sakoulas G.et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 358:2001;207-208.
18. Jones R.N., Della-Latta P., Lee L.V., Biedenbach D.J. Linezolid resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 42:2002;137-139.
19. Anderegg T.R., Jones R.N. Determination of disk diffusion and MIC quality control parameters for AZD2563, a novel long-acting oxazolidinone. Diagn. Microbiol. Infect. Dis. 45:2003;73-76.
20. Turner PJ, Wookey A, Greenhalgh JM, Eastwood M, Clark J. In: 41st Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-1024. p. 222, 2001.
21. Andes DR, Craig WA. In: 41st Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-1038. p. 226, 2001.
22. Craig WA, Andes DR. In: 41st Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-1037. p. 226, 2001.